Efficacy End Points and Dose Analysis of Food and Drug Administration-Approved Novel Drugs in 2020.

Curr Ther Res Clin Exp · 2022 · PMC9310132 · PMID 35899102

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

Highlights • Surrogate end points with accelerated approval have been widely used for approvals, with an increasing trend from 2019 to 2020 (32% vs. 51%).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.